Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Statin safety: a systematic review.

Malcolm Law1, Alicja R Rudnicka

  • 1Wolfson Institute of Preventive Medicine, Barts and The London School of Medicine, London, United Kingdom. m.r.law@qmul.ac.uk

The American Journal of Cardiology
|April 4, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Head-to-Head Comparative Evaluation of Four Commercially Available Artificial Intelligence Systems for Detecting Referable Diabetic Retinopathy in a Tanzanian Population.

Diabetes care·2026
Same author

Response to letter: 'Towards equitable implementation of AI-assisted screening for diabetic retinopathy: Perspectives on digital literacy, trust and system readiness in developing countries'.

Diabetic medicine : a journal of the British Diabetic Association·2026
Same author

Automated retinal image analysis systems to triage for grading of diabetic retinopathy: a large-scale, open-label, national screening programme in England.

The Lancet. Digital health·2025
Same author

What are the perceptions and concerns of people living with diabetes and National Health Service staff around the potential implementation of AI-assisted screening for diabetic eye disease?

Diabetic medicine : a journal of the British Diabetic Association·2025
Same author

Retinal Vessel Traits and Age-Related Eye Disease in the Canadian Longitudinal Study on Aging.

Clinical & experimental ophthalmology·2025
Same author

Generating evidence to support the role of AI in diabetic eye screening: considerations from the UK National Screening Committee.

The Lancet. Digital health·2025
Same journal

Real-World Effectiveness and Tolerability of Sacubitril/Valsartan in Octogenarian Patients With Heart Failure: Results From the PARACHUTER Study.

The American journal of cardiology·2026
Same journal

ECG-Guided Conduction Pathways as a Lever to Shorten Post-TAVI Hospitalization.

The American journal of cardiology·2026
Same journal

Cystatin-C versus creatinine and kidney function in heart failure with preserved ejection fraction: a SOGALDI-PEF analysis.

The American journal of cardiology·2026
Same journal

Balloon-expandable versus Self-expanding Valves in Patients with Small Aortic Annuli Undergoing Transcatheter Aortic Valve Replacement.

The American journal of cardiology·2026
Same journal

Drug-Coated Balloons versus Drug-Eluting Stents following Coronary Atherectomy in Severely Calcified Lesions: A Systematic Review and Meta-Analysis.

The American journal of cardiology·2026
Same journal

Prehospital Statin Therapy and Outcomes in ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2026
See all related articles

Statins, or 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, have a low incidence of serious adverse effects like rhabdomyolysis and myopathy. Combination therapy with certain drugs increases risks, but overall, statins are safe for liver, kidney, and cognitive function.

Area of Science:

  • Pharmacovigilance and Drug Safety
  • Cardiovascular Pharmacology
  • Clinical Epidemiology

Background:

  • 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, are widely prescribed lipid-lowering medications.
  • Understanding the incidence and characteristics of their adverse effects is crucial for patient safety and clinical decision-making.

Purpose of the Study:

  • To systematically review the incidence and characteristics of adverse effects associated with statin therapy.
  • To evaluate specific risks such as rhabdomyolysis, myopathy, liver disease, renal dysfunction, peripheral neuropathy, and cognitive changes.

Main Methods:

  • Systematic review encompassing cohort studies, randomized trials, regulatory authority notifications, and published case reports.
  • Analysis of incidence rates for various adverse events, stratified by statin type, concomitant medications, and patient populations.

Related Experiment Videos

Main Results:

  • Rhabdomyolysis incidence was 3.4 per 100,000 person-years, with a 10% case fatality rate, significantly higher when combined with gemfibrozil.
  • Myopathy incidence was 11 per 100,000 person-years; statins showed fewer hepatobiliary disorders than placebo.
  • Peripheral neuropathy risk was low (12 per 100,000 person-years), with no observed adverse effects on renal function or cognitive abilities in elderly patients.

Conclusions:

  • Statin therapy is associated with a low incidence of serious adverse effects, but risks are elevated with specific drug combinations (e.g., gemfibrozil, CYP3A4 inhibitors).
  • Statins generally demonstrate a favorable safety profile regarding liver, kidney, and cognitive function.
  • Continued pharmacovigilance is essential to monitor and manage potential adverse events associated with statin use.